HUMA Key Statistics, Chart & Performance
The current stock price of HUMA is 1.12 USD. In the past month the price increased by 4.67%. In the past year, price decreased by -75.7%.
HUMA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to HUMA. When comparing the yearly performance of all stocks, HUMA is a bad performer in the overall market: 95.88% of all stocks are doing better.
HUMA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to HUMA. HUMA may be in some trouble as it scores bad on both profitability and health.
HUMA Financial Highlights
Over the last trailing twelve months HUMA reported a non-GAAP Earnings per Share(EPS) of -0.23. The EPS increased by 82.84% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -40.46% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
HUMA Forecast & Estimates
13 analysts have analysed HUMA and the average price target is 8.01 USD. This implies a price increase of 615.56% is expected in the next year compared to the current price of 1.12.
For the next year, analysts expect an EPS growth of 80.41% and a revenue growth 1218.54% for HUMA
HUMA Ownership
About HUMA
Company Profile
Humacyte, Inc. engages in the business of developing and manufacturing off-the-shelf, universally implantable, bioengineered human tissues, advanced tissue constructs, and organ systems with the goal of improving the lives of patients and transforming the practice of medicine. The company is headquartered in Durham, North Carolina and currently employs 218 full-time employees. The company went IPO on 2020-09-22. The firm is engaged in developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The firm develops and manufactures acellular tissues to treat a range of diseases, injuries, and chronic conditions. The company is using its proprietary, scientific technology platform to engineer and manufacture acellular tissue engineered vessels (ATEVs). The firm is also in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD). The firm is also engaged in the preclinical development of coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple cell and tissue applications.
Company Info
HUMACYTE INC
2525 East North Carolina Highway 54
Durham NORTH CAROLINA US
CEO: Rajiv Shukla
Employees: 218
Phone: 19193139633
HUMACYTE INC / HUMA FAQ
What does HUMA do?
Humacyte, Inc. engages in the business of developing and manufacturing off-the-shelf, universally implantable, bioengineered human tissues, advanced tissue constructs, and organ systems with the goal of improving the lives of patients and transforming the practice of medicine. The company is headquartered in Durham, North Carolina and currently employs 218 full-time employees. The company went IPO on 2020-09-22. The firm is engaged in developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The firm develops and manufactures acellular tissues to treat a range of diseases, injuries, and chronic conditions. The company is using its proprietary, scientific technology platform to engineer and manufacture acellular tissue engineered vessels (ATEVs). The firm is also in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD). The firm is also engaged in the preclinical development of coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple cell and tissue applications.
What is the current price of HUMA stock?
The current stock price of HUMA is 1.12 USD. The price increased by 14.29% in the last trading session.
What is the dividend status of HUMACYTE INC?
HUMA does not pay a dividend.
How is the ChartMill rating for HUMACYTE INC?
HUMA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the analyst forecast for HUMA stock?
13 analysts have analysed HUMA and the average price target is 8.01 USD. This implies a price increase of 615.56% is expected in the next year compared to the current price of 1.12.
Is HUMACYTE INC (HUMA) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on HUMA.
What is HUMACYTE INC worth?
HUMACYTE INC (HUMA) has a market capitalization of 209.74M USD. This makes HUMA a Micro Cap stock.